Thursday, October 23, 2014

Medical Professionals: Webinar on How You Can Improve Patient Access to Treatment

Specialty Pharmacies: Strengthening the Team, Smoothing Out the Process
Thursday, Oct. 30
2 p.m. ET/11 a.m. PT 
Register now

Join us for a webinar on improving patient access to treatment. As a medical professional and patient advocate, you are invested in getting your pulmonary hypertension patients access to the therapies that are right for them. You have strategies for overcoming treatment access barriers created by insurers, but what happens when those barriers come from folks who are usually your allies – a patient’s specialty pharmacy?

During this webinar, you will learn how PHA and the Caring Voice Coalition have collaborated with industry to create a Specialty Feedback and Accountability Form, which can serve as a catalyst for change in the specialty pharmacy process.

You will also learn how to:
  • Alert specialty pharmacies to medication delays or other snags in your work with them and receive a prompt response
  • Empower patients to submit comments about the service they receive from their SPs
  • Help PHA, SPs and manufacturers understand best practices or trends taking place within or across SP

Wednesday, October 22, 2014

PHA Online University – 3 New Courses!

PHA Online University, PHA's online learning platform dedicated to enriching the knowledge that medical professionals have of pulmonary hypertension, has exciting new courses! If you are a medical professional, peruse the list below and obtain FREE continuing education units upon successfully completing a course:

Drugs, Toxins, and PAH
Roham Zamanian, MD, Stanford University

  1. Discuss drugs and toxins that are definite and likely risk factors for PAH
  2. Explain how selective serotonin reuptake inhibitor use is related to PAH
  3. Describe possible mechanisms for the development of drug-and-toxin-related PAH
Gender and PAH
Eric Austin, MD, Vanderbilt University
  1. Identify the major risk factors for PAH
  2. Recognize how PAH disproportionately affects females, with more females currently affected for most types of PAH
  3. Recognize that while the prevalence of PAH is higher among females, this does not necessarily mean that females have more sever disease or a more rapid disease progression
Pulmonology Clinical Vignettes
Various Authors
  1. Discuss the hemodynamic, echocardiographic and clinical factors associated with Group 3 pulmonary hypertension
  2. Identify clinical and pathological findings in pulmonary veno-occlusive disease
  3. Evaluate the hemodynamic profile of portopulmonary hypertension and other high flow conditions
  4. Elucidate critical care management of Pulmonary Arterial Hypertension patient

Visit to participate in additional CME courses, view webinars, read scientific abstracts, or access Advances in Pulmonary Hypertension, PHA's medical journal.

We Have a New Twitter Handle

Following PHA on Twitter? We have a new handle! We have switched our Twitter handle from @short_of_breath to @PHAssociation to make it clear that it is PHA's Twitter page. Followers of @short_of_breath are now automatically followers of @PHAssociation. Please tag @PHAssociation from now on.

Visit and follow our Twitter feed @PHAssociation

Tuesday, October 21, 2014

Improving Your Specialty Pharmacy Service

PHA created the Specialty Pharmacy Feedback Form with the Caring Voice Coalition (CVC) as a way for pulmonary hypertension patients, caregivers and medical professionals to share their experiences with specialty pharmacies.

Please help us improve patient care and treatment access by submitting your praise, complaints and concerns today. Your input can help the entire PH community.

Submit a comment

News from Our Partners: Quebec Breathes New Hope into Lives of Those Affected by Pulmonary Arterial Hypertension

The Pulmonary Hypertension Association of Canada (PHA Canada) was pleased to learn that a new treatment option for pulmonary arterial hypertension (PAH) is now being publicly funded in the province of Quebec. On October 1, the Institut national d'excellence en santé et services sociaux (INESSS) recommended that the drug Opsumit (macitentan) be added to the list of drugs covered by the prescription drug insurance plan administered by the Régie de l'assurance maladie du Québec (RAMQ).

Read the full press release

Monday, October 20, 2014

Ella & Kori are Still PHighting!

National PH Advocacy Day is coming up on Nov. 13. Little Ella and Kori (mother of Lilly) have created their Still PHighting videos advocating for better research for pulmonary hypertension. Watch their videos and add your voice by making your Still PHighting video today.

Ella's video:

Kori's video:

Help Us Give You What You Want

PHA is working to ensure that PHA Classroom remains a strong and valuable resource for PH patients, family members and friends. In order to keep providing the PH community with the most relevant information, we need you to tell us what that is. Please take a few minutes to complete this brief survey. Your feedback is extremely valuable to us and will help shape the future of PHA Classroom as well as future PHA programming.

Take short PHA Classroom survey